10 completed, 1 active not recruiting, 1 terminated. 12 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Atrasentan: new trials by email Literature Review of Atrasentan trials Research Report on Atrasentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Atrasentan Spermatogenesis and Testicular Function Atrasentan - Nephropathy, Diabetes | Phase 2 | Completed | AbbVie | 20 | 2015-04-06 | 2019-05-07 |
| A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 48 | 2011-08-01 | 2013-10-25 |
| Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan Atrasentan low dose group, Atrasentan high dose group, Atrasentan placebo group - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 58 | 2011-08-01 | 2017-08-29 |
| Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 149 | 2011-04-01 | 2013-08-28 |
| A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 92 | 2009-06-01 | 2018-06-06 |
| Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer atrasentan hydrochloride - Kidney Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 180 | 2003-07-14 | 2023-06-22 |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma atrasentan hydrochloride, doxil - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 15 | 2003-05-01 | 2012-05-23 |
| Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure Atrasentan - Prostatic Neoplasms | Phase 2 | Completed | Abbott | 200 | 2002-05-01 | 2006-08-15 |
| Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone Atrasentan, Zoledronic Acid (Zometa) - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Completed | Massachusetts General Hospital | 44 | 2001-12-01 | 2010-05-10 |
| A Long Term Safety Study With Atrasentan Atrasentan - Prostate Cancer, Adenocarcinoma | Phase 2 / Phase 3 | Completed | Abbott | 166 | 2001-07-01 | 2007-11-29 |
Diabetic Nephropathies (6) · Renal Insufficiency, Chronic (5) · Prostatic Neoplasms (3) · Proteinuria (3) · Glomerulonephritis, IGA (2) · Kidney Diseases (2) · Urologic Diseases (2) · Adenocarcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1) · Glomerulonephritis (1)
AbbVie (prior sponsor, Abbott) (4) · Abbott (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Eastern Cooperative Oncology Group (1) · Massachusetts General Hospital (1) · Vanderbilt-Ingram Cancer Center (1)
United States (11) · Canada (3) · Spain (3) · Australia (2) · Italy (2) · Puerto Rico (2) · South Korea (2) · United Kingdom (2) · Brazil (1) · France (1) · Germany (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Taiwan (1)
Blai Coll, MD (2) · Darryl Sleep, M.D. (1) · Dennis Andress (1) · Gary Gordon, MD (1) · Marta Crispens, MD (1) · Matthew Smith, MD, PhD (1) · Michael A. Carducci, MD (1)
PMID 28756065, PMID 24722445, PMID 26153128, PMID 33270906, PMID 37254256, PMID 37716952, PMID 38299639, PMID 39899371, PMID 40938675, PMID 41442197, PMID 41904616
2016 (1), 2023 (1)